Dillon, David G; Gurdasani, Deepti; Riha, Johanna; Ekoru, Kenneth; Asiki, Gershim; Mayanja, Billy N; Levitt, Naomi S; Crowther, Nigel J; Nyirenda, Moffat; Njelekela, Marina; +41 more... Ramaiya, Kaushik; Nyan, Ousman; Adewole, Olanisun O; Anastos, Kathryn; Azzoni, Livio; Boom, W Henry; Compostella, Caterina; Dave, Joel A; Dawood, Halima; Erikstrup, Christian; Fourie, Carla M; Friis, Henrik; Kruger, Annamarie; Idoko, John A; Longenecker, Chris T; Mbondi, Suzanne; Mukaya, Japheth E; Mutimura, Eugene; Ndlovu, Chiratidzo E; Praygod, George; Pefura Yone, Eric W; Pujades-Rodriguez, Mar; Range, Nyagosya; Sani, Mahmoud U; Schutte, Aletta E; Sliwa, Karen; Tien, Phyllis C; Vorster, Este H; Walsh, Corinna; Zinyama, Rutendo; Mashili, Fredrick; Sobngwi, Eugene; Adewunmi, Clement; Kamali, Anatoli; seeley, Janet; Young, Elizabeth H; Smeeth, Liam; Motala, Ayesha A; Kaleebu, Pontiano; Sandhu, Manjinder S; African Partnership for Chronic Disease Research (APCDR); (2013) Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. International journal of epidemiology, 42 (6). pp. 1754-1771. ISSN 0300-5771 DOI: https://doi.org/10.1093/ije/dyt198

Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/1462954/

DOI: https://doi.org/10.1093/ije/dyt198

Usage Guidelines:

Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis

David G Dillon,1,2 Deepti Gurdasani,1,2 Johanna Riha,1,2 Kenneth Ekoru,1,2,3 Gershim Asiki,1 Billy N Mayanja,1 Naomi S Levitt,4 Nigel J Crowther,5 Moffat Nyirenda,6 Marina Njelekela,7 Kaushik Ramaiya,8 Ousman Nyan,9 Olonisun O Adewole,10 Kathryn Anastos,11 Livio Azzoni,12 W Henry Boom,13 Caterina Compostella,14 Joel A Dave,15 Halima Dawood,16 Christian Erikstrup,17 Carla M Foure,18 Henrik Friis,19 Annamarie Kruger,20 John A Idoko,21 Chris T Longenecker,22 Suzanne Mbondi,23 Japheth E Mukaya,24 Eugene Mutimura,11 Chiratidzo E Nhlovu,25 George Praygod,26 Eric W Pefura Yone,27 Mar Pujades-Rodriguez,28,29 Nyagosya Range,26 Mahmoud U Sani,30 Alleta E Schutte,18 Karen Sliwa,31 Phyllis C Tien,32 Este H Vorster,33 Corinna Walsh,34 Rutendo Zinyama,35 Fredrick Mashili,7 Eugene Sobngwi,36,37 Clement Adebamowo,38,39 Anatoli Kamali,3 Janet Seeley,3 Elizabeth H Young,1,2 Liam Smeeth,40 Corinna Walsh,34 Rutendo Zinyama,35 Fredrick Mashili,7 Eugene Sobngwi,36,37 Clement Adebamowo,38,39 Anatoli Kamali,3 Janet Seeley,3 Elizabeth H Young,1,2 Liam Smeeth,40 Ayesha A Motala,41 Pontiano Kaleebu,1 Manjinder S Sandhu1,2* and on behalf of the African Partnership for Chronic Disease Research (APCDR)

1Department of Public Health and Primary Care, Institute of Cambridge, Cambridge, UK, 2Geneic Epidemiology Group, Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK, 3MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda, 4Division of Diabetic Medicine and Endocrinology, Department of Medicine, University of Cape Town, Cape Town, South Africa; Chronic Diseases Initiative in Africa, 5Department of Chemical Pathology, National Health Laboratory Service, University of the Witwatersrand Medical School, Johannesburg, South Africa, 6Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi, 7Department of Physiology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania, 8Department of Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania, 9Royal Victoria Teaching Hospital, School of Medicine, University of The Gambia, Banjul, The Gambia, 10Department of Medicine, Obafemi Awolowo University, Ile Ife, Nigeria, 11Women’s Equity in Access to Care & Treatment, Kigali, Rwanda, 12HIV-1 Immunopathogenesis Laboratory, Wistar Institute, Philadelphia, PA, 13Tuberculosis Research Unit, Department of Medicine, Case Western Reserve University, Cleveland, OH, 14Department of Medical and Surgical Sciences, University of Padua, Padua, Italy, 15Division of Diabetic Medicine and Endocrinology, Department of Medicine, University of Cape Town, Cape Town, South Africa, 16Infectious Diseases Unit, Department of Medicine, Grey’s Hospital, Pietermaritzburg, South Africa, 17Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark, 18HART (Hypertension in Africa Research Team), North-West University, Potchefstroom, South Africa, 19Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark, 20Africa Unit for Transdisciplinary Health Research (AUTHeR), North-West University, Potchefstroom, South Africa, 21Department of Medicine, Jos University Teaching Hospital, Jos, Nigeria, 22University Hospitals Case Medical Center, Cleveland, OH, 23German Development Cooperation (GTZ), Yaounde, Cameroon, 24Department of Medicine, Makerere University, Kampala, Uganda, 25Clinical Epidemiology Resource Training Centre, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe, 26National Institute for Medical Research, Dar es Salaam, Tanzania, 27Chest Unit of Jamot Hospital, Yaounde, Cameroon, 28Épicentre, Médecins Sans Frontières, Paris, France, 29Clinical Epidemiology Group, Department of Epidemiology and Public Health, University College London, London, UK, 30Cardiology Unit, Department of Medicine, Aminu Kano Teaching Hospital, Kano, Nigeria, 31Soweto Cardiovascular Research Unit, Chris Hani Baragwanath Hospital, University of the Witwatersrand, Johannesburg, South Africa, 32Department of Medicine, University of California, San Francisco, CA, 33Faculty of Health Sciences, North-West University, Potchefstroom, South Africa, 34Department of Nutrition and Dietetics, University of the Free State, Bloemfontein, South Africa, 35Medical Research Council of Zimbabwe, Department of Medical Laboratory Sciences, University of Zimbabwe, Harare, Zimbabwe, 36Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon, 37Institute of Health and Society, University of Newcastle, Newcastle, UK, 38Institute of Human Virology, Abuja, Nigeria, 39Department of Epidemiology and Public Health, Institute of Human Virology and Greenbaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, 40Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK and 41Department of Diabetes and Endocrinology, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa

*Corresponding author. International Health Research Group, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. E-mail: ms23@sanger.ac.uk
Background
Sub-Saharan Africa (SSA) has the highest burden of HIV in the world and a rising prevalence of cardiometabolic disease; however, the interrelationship between HIV, antiretroviral therapy (ART) and cardiometabolic traits is not well described in SSA populations.

Methods
We conducted a systematic review and meta-analysis through MEDLINE and EMBASE (up to January 2012), as well as direct author contact. Eligible studies provided summary or individual-level data on one or more of the following traits in HIV+ and HIV-, or ART+ and ART- subgroups in SSA: body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides (TGs) and fasting blood glucose (FBG) or glycated hemoglobin (HbA1c). Information was synthesized under a random-effects model and the primary outcomes were the standardized mean differences (SMD) of the specified traits between subgroups of participants.

Results
Data were obtained from 49 published and 3 unpublished studies which reported on 29,755 individuals. HIV infection was associated with higher TGs [SMD, 0.26; 95% confidence interval (CI), 0.08 to 0.44] and lower HDL (SMD, −0.59; 95% CI, −0.86 to −0.31), BMI (SMD, −0.32; 95% CI, −0.45 to −0.18), SBP (SMD, −0.40; 95% CI, −0.55 to −0.25) and DBP (SMD, −0.34; 95% CI, −0.51 to −0.17). Among HIV+ individuals, ART use was associated with higher LDL (SMD, 0.43; 95% CI, 0.14 to 0.72) and HDL (SMD, 0.39; 95% CI, 0.11 to 0.66), and lower HbA1c (SMD, −0.34; 95% CI, −0.62 to −0.06). Fully adjusted estimates from analyses of individual participant data were consistent with meta-analysis of summary estimates for most traits.

Conclusions
Broadly consistent with results from populations of European descent, these results suggest differences in cardiometabolic traits between HIV-infected and uninfected individuals in SSA, which might be modified by ART use. In a region with the highest burden of HIV, it will be important to clarify these findings to reliably assess the need for monitoring and managing cardiometabolic risk in HIV-infected populations in SSA.

Keywords
HIV, ART, cardiometabolic disease, sub-Saharan Africa

Introduction
Sub-Saharan Africa (SSA) has the highest burden of HIV in the world, with approximately 22.9 million prevalent cases and 1.9 million new infections recorded in 2010. The estimated 1.3 million people who died of HIV-related illnesses in SSA in 2009 comprised 72% of the global mortality attributable to the epidemic. Anti-retroviral therapy (ART) coverage in this region has rapidly increased over the past decade, with 49% of eligible cases receiving treatment in 2010. Expanding use of ART has led to a notable decline in HIV-associated morbidity and death in SSA. As life expectancy among HIV-infected people improves, it is crucial to understand the long-term impact of HIV and its treatment in this region. Parallel to the changing landscape of HIV care, the burden of cardiometabolic diseases in SSA is increasing, with expected deaths attributable to cardiovascular disease projected to double to 2.4 million in 2030 relative to reports from 2000. These data suggest that cardiometabolic diseases will become a major health problem in SSA, competing with infectious diseases for limited health resources.

Several studies in populations of European descent suggest that HIV infection and ART are independently associated with an increased risk of cardiometabolic...
disease, including cardiovascular disease, dyslipidaemia and type 2 diabetes (T2D). 

However, findings appear to be inconsistent even within these studies, and the true direction and magnitude of these associations remain uncertain. A large prospective study reported a 26% relative increase in the rate of myocardial infarction (MI) per year of ART exposure during the first 4–6 years of use. 

In 2003, to address possibly increased cardiometabolic risk in this group, the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group published guidelines specifically for management of dyslipidaemia in HIV-infected individuals. 

However, these guidelines were primarily based on evidence from European studies and have not been widely implemented in SSA. 

Importantly, there is some evidence to suggest that there may be differences in cardiometabolic risk profiles in people of African descent compared with people of European descent, implying that the aetiology of cardiometabolic disease, and the distribution and spectrum of risk factors, might differ in African populations. Examples include the differential tobacco usage patterns in SSA compared with other regions, as well as differences in alcohol consumption patterns in populations of African descent. Furthermore, it has been reported that the predominant virus strains responsible for HIV infection in SSA are HIV-1, group M (major) subtypes A and C, which differ as much as 30% in their genomes from HIV-1 subtype B, responsible for the infections in North America and Europe. The clinical consequences of these subtype differences are, as yet, unclear. Additionally, there is precedent for differences in the efficacy of infectious disease treatments in individuals of African descent, such as that seen in interferon treatment for chronic hepatitis C. These potential differences in HIV and ART associations with cardiometabolic traits, if any, have not been reliably clarified.

In this context, it is important to examine possible associations between HIV infection, ART treatment and cardiometabolic traits in SSA. Assessing these associations will help inform and guide future research and public health responses in the region. We therefore conducted a systematic review and meta-analysis of published and unpublished data to assess these associations in SSA.

### Methods

#### Search strategy and identification of studies

This systematic review was conducted and reported in accordance with the PRISMA guidelines. This study focused on differences in cardiometabolic traits between HIV-infected and uninfected individuals, and between those receiving and not receiving treatment. A group of eight commonly accepted cardiometabolic traits were selected a priori for inclusion in this analysis: body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), serum high-density lipoprotein cholesterol (HDL), serum low-density lipoprotein cholesterol (LDL), triglycerides (TGs), fasting blood glucose (FBG) and glycated haemoglobin (HbA1c). We did not examine lipodystrophy as a risk factor due to the marked variability in assessment criteria in the literature. Using a structured search strategy (Supplementary Figures 1–2, available as Supplementary data at IJE online), PUBMED and EMBASE databases were queried for articles written in English before the 1 January 2012. Published abstracts were reviewed and assessed for inclusion in the study. Those meeting the following inclusion criteria were listed for full text review (Box 1): described data on the relevant cardiometabolic traits in comparable HIV+ and HIV- populations, or comparable ART+ and ART naive groups; and included adult (aged 18 years or over) Black participants based in SSA, as defined by the WHO African region. Comparability between groups was defined as data collection using similar study procedures for both individuals infected and those uninfected with HIV, or ART users and nonusers. Two reviewers (D.G.D. and J.R.) independently assessed studies for eligibility. Consensus for eligibility between the two reviewers was >95%. Any discrepancies in eligible studies listed were resolved by consensus discussion. Studies not meeting both eligibility criteria were not included in the final review. We excluded case reports with fewer than five participants. Electronic searches were supplemented by cross-

### Box 1 Eligibility criteria for inclusion in the systematic review

| Inclusion criteria |
|--------------------|
| **Population** | ● A population or cohort consisting of adult Black participants based in sub-Saharan Africa, as defined by the World Health Organization African region |
|                 | ● Consists of comparable HIV+ and HIV− populations or comparable ART+ and ART− naive groups |
| **Outcome**     | ● Presents data on at least one of the following: body mass index, systolic blood pressure, diastolic blood pressure, serum high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglycerides, fasting blood glucose or HbA1c |

ART, antiretroviral therapy.
referencing of cited reference lists from retrieved articles and reviews.

Following full text review of all potentially eligible articles, those identified as fulfilling the inclusion criteria (Figure 1) were collated for analysis. We contacted the corresponding authors of all eligible articles, inviting their participation in this study. We worked with these authors to confirm the accuracy of extracted published data and to obtain additional relevant unpublished data for this review. Responses were received from 69.7% of the contacted authors, of whom 68.4% agreed to collaborate on this meta-analysis. We received data from 85.0% of collaborating groups. All studies were reviewed and approved by their respective research ethics committees. Full details of the search strategy, all identified articles and reasons for exclusion if applicable can be found in Supplementary Figures 1–2 and Supplementary Table 1, available as Supplementary data at IJE online.

Data abstraction and synthesis

Year, country, publication status (published/unpublished) and study type (cohort/case-control) were recorded for each study. The following data were extracted for relevant subgroups (HIV+, HIV−, ART+, ART−) within each study: number of individuals, mean age, sex distribution, means and SDs for pre-specified cardiometabolic traits, and fasting status at time of measurement (Supplementary Table 2, available as Supplementary data at IJE online).

HIV status was defined by classification in each individual study without alteration. HIV infection was considered irrespective of ART status, and individuals receiving ART were not excluded from this group. We defined 'ART use' as receipt of ART medication at the time of cardiometabolic trait measurement in the original report. Due to heterogeneous study designs and the frequent lack of specific ART-related data in non-ART-centric studies, no specific data were gathered on
ART type, ART duration pre-measurement or calendar period during receipt of ART. In accordance with the International System of Units (SI), all cardiometabolic measurements were converted to mmol/l, %, mmHg or kg/m², as appropriate.

Individual-level participant data from the General Population Cohort Study

In order to explore the impact of residual confounding on our estimates, and to assess consistency between unadjusted estimates from summary-level data and fully adjusted estimates from individual-level data, we also analysed previously unpublished individual-level data from one of the studies included in the meta-analysis—the General Population Cohort (GPC) study. These individual-level analyses were performed on 5586 participants, comprising 18.8% of the total number of participants included in this meta-analysis.

The GPC study is a population-based cohort study of approximately 22,000 individuals living in rural south-west Uganda. This cohort was established in 1989 by the Medical Research Council Programme on AIDS in Uganda to assess trends in the prevalence and incidence of HIV infection in the population. Since then, an annual census is taken of the entire population to collect basic demographic information. From this census, consenting individuals are invited to take part in an interviewer-mediated questionnaire, to have their biophysical measurements taken and to have blood samples drawn for analysis. GPC participants found to be HIV-infected are invited to join the Rural Clinical Cohort for further follow-up. The Rural Clinical Cohort encompasses all consenting HIV+ participants within the GPC and gathers data on their health and disease progression, in addition to providing care and access to ART. Full details of the cohort structure, measurement techniques and the annual HIV survey have been published elsewhere.

In the GPC, detailed individual-level data were collected on HIV status, ART, age, sex, BMI, lipid factors, blood pressure, HbA1c levels, education status, smoking and household-level clustering (Supplementary Table 3, available as Supplementary data at IJE online). This study was approved by the Science and Ethics Committee of the Uganda Virus Research Institute, the Uganda National Council for Science and Technology and the East of England-Cambridge South (formerly Cambridgeshire 4) NHS Research Ethics Committee UK.

Statistical analysis

Because we anticipated heterogeneity among results of studies due to potential differences in underlying genetic susceptibility, health care infrastructure and monitoring of chronic disease among individuals with and without HIV and those using ART, we used random-effects meta-analyses in our primary analyses. However, as results from random-effects meta-analyses may not always be conservative, we also compared random and fixed-effects estimates. We examined standardized mean difference (SMD) between relevant groups (HIV+, HIV−, ART+, ART−) as the primary measure of association for each trait for ease of interpretation. This summary measure allows the reader to compare differences in disparate cardiometabolic traits on a single scale, and comprehend these differences without an underlying knowledge of the normal values and distribution of the traits in question. The I² statistic was used to assess heterogeneity between studies.

We initially explored potential sources of heterogeneity through the visual inspection of forest and Galbraith plots. Meta-regression and stratified analysis approaches were then used to assess the contribution of study-level variables to heterogeneity in summary estimates. Variables assessed were: study type (cohort/case-control), study size, date of publication, study location, publication status (published/unpublished), mean participant BMI, mean participant age, sex distribution, mean difference in BMI between groups, mean age difference between groups, and proportion of HIV-infected individuals on ART in each study (for comparisons between HIV-infected and uninfected individuals). For evaluation of heterogeneity by study location, studies were initially grouped according to UN geographical sub-areas as follows: East Africa, Central Africa, West Africa and Southern Africa. However, as data gathered from West and Central African regions were limited, these were collapsed for further analysis. Factors were identified as contributing to between-study heterogeneity, when a substantial reduction in heterogeneity was observed on adjustment for the factor in meta-regression. Heterogeneity resulting from differing ART drug class could not be explored because of the small number of studies that reported this information. Furthermore, we could not explore heterogeneity by participant fasting status, as a large proportion of studies did not report status during blood draw for lipid traits and all studies reporting glucose measurements were on fasted individuals. We also sought to systematically explore the potential impact of outliers on estimates from meta-analysis for each by evaluating the stability of meta-analysed SMD estimates to sequential exclusion of single studies.

In order to assess consistency between estimates from adjusted individual-level data and unadjusted summary data, we carried out individual participant data analysis on a subset of the meta-analytical data using the GPC study. We calculated SMD estimates for the differences in cardiometabolic traits associated with HIV infection and ART use, adjusted for age, sex, BMI, education level, smoking status and ART use (among HIV-infected individuals), using linear mixed-effects models, including random effects for data clustering at household and village levels. Age and BMI were added as continuous variables whereas
sex, education level, smoking status and ART use were all added as categorical variables. All analyses were conducted in Stata version 11.0.

**Results**

We analysed 52\textsuperscript{29–77} datasets from 14 countries (Figure 2), providing study-level data on 29755 participants (23119 from previously published studies and 6636 participants from unpublished studies; Unpublished data acquired from personal communications with C. Fourie, A. Schutte, and the MRC/UVRI; Table 1). Studies were broadly distributed across the three regions in SSA, with more participants from East Africa than Southern Africa or West & Central Africa (Table 1). Of these 52 studies, nine were conducted among HIV and tuberculosis co-infected patients, two among malnourished populations and two among pregnant women. None of these study-level factors explained an appreciable portion of between study heterogeneity in meta-regression analyses (Table 2).

**HIV and cardiometabolic traits**

In this meta-analysis of summary data from up to 29755 study participants, we found that HIV infection was associated with lower mean BMI (SMD, $-0.32$; 95% CI, $-0.45$ to $-0.18$) (Figure 3). For blood lipids, HIV infection was associated with higher mean TG levels (SMD, 0.26; 95% CI, 0.08 to 0.44) and lower mean HDL levels (SMD, $-0.59$; 95% CI, $-0.86$ to $-0.31$), whereas no marked difference in mean LDL was observed between HIV-infected and uninfected individuals (SMD, $-0.16$; 95% CI, $-0.34$ to 0.03). HIV infection was also associated with lower DBP (SMD, $-0.34$; 95% CI, $-0.51$ to $-0.17$) and SBP (SMD, $-0.40$; 95% CI, $-0.55$ to $-0.25$) (Figure 3). Based on summary data from up to 6064 study participants, we did not find any evidence of association between HIV infection and fasting blood glucose or HbA1c (Figure 3). Study-level and combined summary estimates for each trait are illustrated in Supplementary Figures 3–10, available as Supplementary data at IJE online. Comparison of combined SMD estimates from fixed-effect and random-effect meta-analysis showed that the latter were consistently more conservative across all traits (Supplementary Figure 11, available as Supplementary data at IJE online).

We observed marked heterogeneity among combined SMDs for all traits (Figure 3). However, based on both stratified and meta-regression analyses, we found no consistent explanation for overall heterogeneity among studies for each trait, including study-level

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{countries_map.png}
\caption{Countries contributing data, by region}
\end{figure}
factors such as study size, year of study, publication status or study type (Table 2). Assessment of estimates stratified by study-level characteristics suggested that study location may have a modest impact on the magnitude of the association for some traits (Supplementary Figures 12–19, available as Supplementary data at IJE online). However, the addition of these variables into meta-regression did not affect heterogeneity estimates (Table 2 and Supplementary Figures 12–19, available as Supplementary data at IJE online). In addition, heterogeneity among SMDs in studies could not be explained by confounding factors measured at the study level (Table 2).

Visual inspection of forest and Galbraith plots suggested a variety of outlying studies for several cardiometabolic traits (Supplementary Figures 3–10 and 20–27, available as Supplementary data at IJE online), which may also impact on analyses exploring the determinants of heterogeneity. Sensitivity analyses examining the impact of extreme outlying studies on the combined SMDs of the cardiometabolic traits showed no material change in combined SMDs for traits found to be associated with HIV infection (Supplementary Tables 4–11, available as Supplementary data at IJE online). However, exclusion of a single outlying study led to associations, where there had previously been none, for two additional cardiometabolic traits—LDL and glucose. Table 3 describes the range of SMDs obtained for each trait after sequential exclusion of individual studies.

**ART and cardiometabolic traits**

In analyses based on up to 3348 HIV+ individuals, ART exposure was found to be associated with higher HDL (SMD, 0.39; 95% CI, 0.11 to 0.66) and LDL levels (SMD, 0.43; 95% CI, 0.14 to 0.72) and lower HbA1c levels (SMD, −0.34; 95% CI, −0.62 to −0.06) (Figure 4). By contrast, no appreciable differences were observed for BMI (SMD, 0.12; 95% CI, −0.11 to 0.34) or TGs (SMD, 0.09; 95% CI, −0.04 to 0.21) between ART users and non-users (Figure 4).

Based on data from up to 2087 participants, we did not detect any association between ART use and SBP, DBP or fasting blood glucose (Figure 4). Individual study SMDs and combined estimates for each cardiometabolic trait are presented in Supplementary Figures 28–35, available as Supplementary data at IJE online. Estimates from random-effects meta-analysis were consistently more conservative than those from fixed-effects meta-analysis for all traits (Supplementary Figure 36, available as Supplementary data at IJE online).

Similar to analyses between HIV infection and cardiometabolic traits, we found marked heterogeneity among SMDs for all traits (Figure 4). However, stratified and meta-regression analyses did not consistently explain heterogeneity in estimates among studies (Table 2 and Supplementary Figures 37–44, available as Supplementary data at IJE online). Again, assessment of potential study-level effect-modification factors through meta-regression did not show clear evidence to suggest that these explained heterogeneity among studies (Table 2 and Supplementary Figures 37–44, available as Supplementary data at IJE online).

Based on visual assessments of forest and Galbraith plots, we found evidence of several outlying studies assessing the association between ART use and cardiometabolic traits (Supplementary Figures 28–35 and 45–52, available as Supplementary data at IJE online). Nevertheless, none of the combined SMDs that were associated with ART use materially changed during sequential exclusion (Table 3). We did, however, observe a change in SMD estimates for DBP on exclusion of one study, and for TGs on exclusion of one study, leading to associations between ART use and...
### Table 2

**I²-values for residual heterogeneity after meta-regression incorporating study level characteristics**

| HIV associations | Unadjusted | Study type | Study size | Date of study | Location | Publication status | Tuberculosis co-infection | Pregnant participants | Malnourished participants | Mean study BMI | Mean study age | Mean study sex distribution | Mean BMI difference between HIV+/HIV− or ART+/ART− | Mean age difference between HIV+/HIV− or ART+/ART− | Proportion of HIV+ participants on ART |
|------------------|------------|------------|------------|---------------|----------|-------------------|--------------------------|----------------------|----------------------------|----------------|-------------|----------------------------|--------------------------------|--------------------------------|-----------------------------|
| **BMI**          | 93.4 (36)  | 93.4/93.3 * (36) | 93.4/93.6 (36) | 93.4/92.8 (36) | 93.4/93.3 (36) | 93.4/93.3 (36) | 93.4/92.1 (36) | 93.4/93.1 (36) | 93.4/93.4 (36) | 93.4/93.2 (36) | 95.1/95.4 (18) | 95.3/95.1 (25) | N/A | 95.1/95.2 (18) | 94.9/94.9 (12) |
| **TGs**          | 91.6 (15)  | 91.6/87.6 * (15) | 91.6/92.1 (15) | 91.6/90.3 (15) | 91.6/90.1 (15) | 91.6/92.1 (15) | – | – | – | 82.4/72.7 (13) | 65.5/70.8 (6) | 92.4/92.9 (12) | 82.4/83.8 (13) | 65.5/71.4 (6) | 91.6/95.5 (10) |
| **LDL**          | 91.1 (14)  | 91.1/91.3 (14) | 91.1/91.8 (14) | 91.1/91.2 (14) | 91.1/91.7 (14) | – | – | – | 92.3/92.5 (12) | 18.3/0.00 (6) | 90.0/90.9 (11) | 92.3/93.0 (12) | 18.3/14.1 (6) | 91.9/90.2 (10) |
| **HDL**          | 96.1 (14)  | 96.1/96.3 (14) | 96.1/94.8 (14) | 96.1/96.2 (14) | 96.1/95.0 (14) | – | – | – | 95.7/95.9 (12) | 93.6/92.7 (6) | 96.6/96.2 (11) | 95.7/95.8 (12) | 91.6/7.3 *** (6) | 97.3/97.0 (10) |
| **SBP**          | 84.1 (15)  | 84.1/82.8 (15) | 84.1/82.9 (15) | 84.1/84.6 (15) | 84.1/84.1 (15) | 84.1/85.1 (15) | – | – | – | 86.1/87.3 (13) | 51.7/56.5 (8) | 78.3/76.6 (11) | 86.1/86.9 (13) | 51.7/53.0 (8) | 76.6/20.2 (4) |
| **DBP**          | 87.6 (15)  | 87.6/84.1 * (15) | 87.6/86.1 (15) | 87.6/88.1 (15) | 87.6/88.7 (15) | 87.6/89.1 (15) | – | – | – | 88.3/89.1 (13) | 76.7/80.0 (8) | 87.7/88.6 (11) | 88.3/83.6 * (13) | 76.7/77.1 (8) | 95.2/96.8 (4) |
| **Glucose**      | 98.5 (6)   | 98.5/96.5 (6) | 98.5/98.7 (6) | 98.5/98.8 (6) | 98.5/98.7 (6) | 98.5/98.7 (6) | – | – | – | 98.8/99.0 (5) | – | 98.9/96.9 (4) | 98.9/98.7 (5) | – | 99.3/99.0 (3) |
| **HbA1c**        | 82.5 (3)   | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| **ART associations** |           |            |            |               |          |                    |                          |                      |                        |                           |                      |                          |                      |                      |                      |
| **BMI**          | 91.0 (13)  | 91.0/88.2 * (13) | 91.0/91.4 (13) | 91.0/91.7 (13) | 91.0/91.3 (13) | 91.0/90.8 (13) | 91.0/92.0 (13) | – | – | 91.0/91.9 (13) | 91.4/91.2 (12) | 76.7/77.9 (6) | 95.7/96.5 (6) | N/A | 76.7/48.7 (4) | N/A |
| **TGs**          | 65.7 (10)  | 65.7/69.5 (10) | 65.7/68.9 (10) | 65.7/69.5 (10) | 65.7/25.4 * (10) | 65.7/69.5 (10) | – | – | – | 69.8/67.2 (7) | 50.2/61.8 (4) | 0.0/0.0 (3) | 69.8/74.7 (1) | 50.2/37.3 (4) | N/A |
| **LDL**          | 93.4 (10)  | 93.4/94.1 (10) | 93.4/92.5 (10) | 93.4/93.5 (10) | 93.4/94.0 (10) | 93.4/93.8 (10) | – | – | – | 89.2/89.9 (7) | 70.9/63.4 (4) | 92.8/88.9 (3) | 89.2/88.7 * (7) | 70.9/67.9 (4) | N/A |
| **HDL**          | 92.9 (10)  | 92.9/92.3 (10) | 92.9/89.2 * (10) | 92.9/93.1 (10) | 92.9/93.1 (10) | 92.9/93.1 (10) | – | – | – | 85.3/86.6 (7) | 93.6/93.3 (4) | 93.6/90.0 (1) | 85.3/85.6 (7) | 91.6/89.7 (4) | N/A |
| **SBP**          | 83.4 (6)   | 83.4/71.7 (6) | 83.4/59.6 (6) | 83.4/84.3 (6) | 83.4/84.3 (6) | 83.4/84.3 (6) | – | – | – | 83.4/84.1 (6) | – | – | 83.4/81.2 (6) | – | N/A |
| **DBP**          | 64.6 (6)   | 64.6/55.7 (6) | 64.6/28.7 (6) | 64.6/71.3 (6) | 64.6/68.6 (6) | 64.6/71.6 (6) | 64.6/70.0 (6) | – | – | – | 64.6/67.7 (6) | – | – | 64.6/61.6 (6) | – | N/A |
| **Glucose**      | 90.4 (5)   | 90.4/92.3 (5) | 90.4/85.5 (5) | 90.4/91.6 (5) | 90.4/85.7 (5) | 90.4/92.8 (5) | – | – | – | 90.4/85.2 (5) | – | – | 90.4/91.8 (5) | – | N/A |
| **HbA1c**        | 56.9 (2)   | – | – | – | – | – | – | – | – | – | – | – | – | – | – |

All values presented as I-squared percent without addition of the study level characteristic/I-squared percent with the addition of the study level characteristic (number of studies with relevant data).

N/A, not applicable; –, insufficient information; BMI, body mass index; TGs, triglycerides; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; ART, antiretroviral therapy.

*P-value ≤ 0.05; **P-value ≤ 0.01; ***P-value ≤ 0.001.
these cardiometabolic traits where there had previously been none. Individual combined SMDs for each sensitivity analysis are presented in Supplementary Tables 12–19, available as Supplementary data at IJE online.

Individual participant data analysis
To explore the potential effects of confounding on association estimates, we carried out individual participant data analysis in a subset of data adjusting for all potential confounders. Analysis of individual participant data from 5586 individuals in the GPC study, Uganda, was broadly consistent with summary estimates from meta-analysis for associations between HIV, ART and cardiometabolic traits. HIV infection was associated with lower TGs (SMD, 0.28; 95% CI, 0.17 to 0.39) and lower LDL (SMD, −0.18, 95% CI, −0.29 to −0.07), HDL (SMD, −0.26; 95% CI, −0.37 to −0.14) and SBP (SMD, −0.17; 95% CI, −0.26 to −0.08) when adjusted for age, sex, BMI, ART exposure, education level and smoking status and clustered by village and household status (Figure 5). In addition, we found a weak association between HIV infection and higher HbA1c levels (SMD, 0.14; 95% CI, 0.04 to 0.24) in the fully adjusted model (Figure 5). Comparing ART exposed and unexposed HIV-infected individuals, we found associations between ART use and higher LDL (SMD, 0.18; 95% CI, 0.02 to 0.34), HDL cholesterol levels (SMD, 0.67; 95% CI, 0.47 to 0.87), lower TGs (SMD, −0.21; 95% CI, −0.38 to −0.03) and HbA1c levels (SMD, −0.23; 95% CI, −0.37 to −0.08). In both analyses, fully adjusted estimates showed stronger associations than unadjusted estimates, suggesting that in this situation unadjusted estimates are more conservative than fully adjusted estimates. Sub-analyses comparing associations across all three subgroups (HIV−, HIV+/ART− and HIV+/ART+) in the GPC population are presented in Supplementary Table 3, available as Supplementary data at IJE online.

Discussion
In this meta-analysis of data from up to 29755 individuals in SSA, HIV infection was found to be associated with lower BMI, lower SBP, lower DBP, higher TGs and lower HDL levels. Among HIV-infected individuals, ART treatment was associated with higher LDL and HDL, as well as lower HbA1c levels.
Heterogeneity among study estimates did not appear to be consistently explained by study-level factors, including potential confounders. These findings are broadly consistent with published results from populations of European descent. In a region with approximately 22.9 million cases of HIV and many millions of people on ART, it will be important to clarify these findings to reliably assess the need for monitoring and managing cardiometabolic risk in SSA populations.

Whereas several studies have documented lipid and glucose abnormalities in HIV-infected individuals and those treated with ART, the pathophysiology of these differences remains unclear. Higher levels of TGs in HIV-infected individuals have been attributed to higher concentrations of very-low-density lipoprotein cholesterol (VLDL) in plasma, and enrichment of LDL and HDL particles for TGs. TG clearance has been shown to be decreased in AIDS and HIV+ individuals, and elevated cytokine levels, such as IFN-alpha, might be involved in slowed clearance. It has been suggested that these changes may be due, in part, to the inflammatory effects of the viral infection. Several mechanisms have been outlined for the association between ART and dyslipidaemia, including reduced synthesis of cis-9-retinoic acid, leading to dysregulation of adipocyte differentiation and apoptosis, increased hepatic TG synthesis, increase in dense LDL particles, a shift towards TG-rich VLDL and increase in apolipoprotein C-III- and apolipoprotein E-containing particles. However, mechanisms are thought to be different for the various classes of ART drugs.

Associations between HIV, ART and blood lipids observed in this meta-analysis are consistent with studies from Europe and North America, which show that HIV infection in ART-naïve individuals is associated with hypertriglyceridaemia and lower HDL and LDL levels, whereas ART use is associated with higher HDL and LDL levels. Both the

| Table 3 Sensitivity analysis of the change in combined standardized mean difference estimates after sequential exclusion of single studies |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| Combined estimate obtained before sequential exclusion | Range of SMDs obtained from sequential exclusion of individual studies | Instance in which exclusion of a single study produced a change in interpretation |
| SMD (95% CI) I² | SMD (95% CI) I² | SMD (95% CI) I² |
| HIV associations | | |
| BMI | −0.32 (−0.45 to −0.18) 93.4% | −0.34 to −0.26 | – |
| TGs | 0.26 (0.08 to 0.44) 91.6% | 0.16 to 0.30 | – |
| LDL | −0.16 (−0.34 to 0.03) 91.1% | −0.27 to −0.11 | – |
| HDL | −0.59 (−0.86 to −0.31) 96.1% | −0.65 to −0.44 | – |
| SBP | −0.40 (−0.55 to −0.25) 84.1% | −0.44 to −0.37 | – |
| DBP | −0.34 (−0.51 to −0.17) 87.6% | −0.39 to −0.26 | – |
| Glucose | 0.35 (−0.35 to 1.06) 98.5% | −0.14 to 0.50 | – |
| HbA1c | −0.07 (−0.39 to 0.25) 82.5% | −0.16 to 0.04 | – |
| ART associations | | |
| BMI | 0.12 (−0.11 to 0.34) 91.0% | 0.02 to 0.15 | – |
| TGs | 0.09 (−0.04 to 0.21) 65.7% | 0.05 to 0.12 | – |
| LDL | 0.43 (0.14 to 0.72) 93.4% | 0.34 to 0.53 | – |
| HDL | 0.39 (0.11 to 0.66) 92.9% | 0.31 to 0.49 | – |
| SBP | 0.05 (−0.19 to 0.28) 83.4% | −0.3 to 0.16 | – |
| DBP | 0.06 (−0.10 to 0.22) 64.6% | 0.00 to 0.16 | – |
| Glucose | −0.23 (−0.61 to 0.16) 90.4% | −0.34 to −0.04 | – |
| HbA1c | −0.34 (−0.62 to −0.06) 56.9% | −0.23 to −0.52 | – |

–, combined SMD did not change statistical significance due to the sequential exclusion of any single study; CI, confidence interval; BMI, body mass index; TGs, triglycerides; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; ART, antiretroviral therapy.
magnitude and the direction of HIV and ART associations with HDL and LDL are consistent with reported estimates. We did not find an association between ART and TGs in this study, which is inconsistent with a meta-analysis of randomized clinical trials reporting a positive association between first-line ART and TGs, with stronger associations observed in protease inhibitor-treated patients. Furthermore, results for the association between ART exposure and TG were inconsistent between meta-analysis of summary data and individual participant data from the GPC. These inconsistencies are likely to be due to different treatment regimens across studies and infrequent use of protease inhibitors in comparison with nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors (NNRTI) in SSA. Indeed, regimens based on nevirapine (an NNRTI drug) are the most commonly used in the GPC HIV+ patient population, which may explain the inverse association between ART exposure and TG in the individual-level analysis, as previously noted.

Similarly, the inverse association between HIV infection and BMI in SSA populations is consistent with previously published findings in populations of European descent. Advanced stages of HIV have been consistently associated with a rapid decrease in BMI. There is also clear evidence supporting the role of HIV infection and ART use in the pathogenesis of lipodystrophy, and the effects these changes in body-fat redistribution may have on cardiometabolic traits. However, in our individual-level dataset neither HIV nor ART is associated with differences in BMI. Thus, it is unclear what effect BMI has on the relationship among HIV, ART and cardiometabolic traits in these populations.

Our analyses found that individuals infected with HIV in SSA had lower DBP and SBP than uninfected controls, regardless of ART status. Previous studies assessing the associations between HIV, ART and blood pressure have been inconsistent, with some studies suggesting increased risk of hypertension with ART, some reporting no association with HIV or ART21,79–90 and others supporting the findings of this meta-analysis. There is no clear biological mechanism that might account for such associations. One explanation for our findings may be residual confounding in our meta-analysis of study-level data. Indeed, both BMI and blood pressure were inversely associated with HIV in our data. However, individual participant analysis in a subset of data showed the

---

**Figure 4** Summary of overall estimates from random-effects meta-analyses of associations between ART and individual cardiometabolic risk factors. SMD, standardized mean difference; CI, confidence interval; BMI, body mass index; TGs, triglycerides; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; ART, antiretroviral therapy.
from several large prospective and cross-sectional studies, ART use and fasting blood glucose levels. Results require further evaluation.

HbA1c, glycated haemoglobin; ART, antiretroviral therapy; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Whereas this finding is consistent with findings previously published results, only a small number of studies reported blood pressure measurements in both ART+ and ART- populations, suggesting these results require further evaluation.

We did not find an association between HIV infection, ART use and fasting blood glucose levels. Whereas this finding is consistent with findings from several large prospective and cross-sectional studies, it does not agree with findings from some large studies in populations of European descent that have reported associations between HIV infection, ART use and increased risk of T2D. Differences in cardiometabolic traits among ART users and non-users may have important implications for the management of people infected with HIV. Antiretroviral therapy has greatly improved the survival of HIV-infected patients living today; however, the mortality rates in HIV patients are still higher than in the general population and the proportion of deaths due to non-HIV-related causes including cardiometabolic diseases, is increasing. Dyslipidaemia is common among patients with HIV and has been shown to be associated with increased cardiovascular disease risk in this patient population. Furthermore, there is evidence to support an independent role of HIV infection on cardiometabolic disease risk, after accounting for traditional risk factors and exposure to ART.

In the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) cohort of 23,468 HIV-infected patients, higher total serum cholesterol and TGs and presence of diabetes were associated with an increased risk of myocardial infarction. Differences in average levels of cardiometabolic traits among subpopulations might also result in important differences in cardiovascular disease risk. For example, a 1-SD increase in LDL and HDL each were associated with a relative risk of 1.4 and 0.6, respectively, for coronary heart disease in the Atherosclerosis Risk in Communities Study (ARIC).

Figure 5 Participant-level data on the associations of HIV and ART with cardiometabolic traits in the General Population Cohort, adjusted for different amounts of individual-level confounding. Full adjustment includes adjustment for data clustering, ART exposure (when comparing HIV+ and HIV− subgroups), age, sex, BMI, education level and smoking status. SMD, standardized mean difference; CI, confidence interval; BMI, body mass index; TGs, triglycerides; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; ART, antiretroviral therapy.

| Risk factor | SMD (95% CI) |
|-------------|-------------|
| HIV | ART |
| **UNADJUSTED** | | |
| BMX | -0.03 (-0.12, 0.06) | -0.11 (-0.29, 0.07) |
| TG | 0.18 (0.09, 0.26) | -0.18 (-0.36, -0.01) |
| LDL | -0.15 (-0.24, -0.07) | 0.22 (0.06, 0.38) |
| HDL | 0.02 (0.07, 0.11) | 0.72 (0.53, 0.91) |
| SBP | -0.21 (-0.35, -0.10) | 0.16 (0.03, 0.38) |
| DBP | 0.00 (0.08, 0.09) | 0.09 (0.02, 0.20) |
| HbA1c | 0.03 (-0.06, 0.11) | -0.21 (-0.36, -0.06) |
| **FULLY ADJUSTED** | | |
| BMX | 0.28 (0.17, 0.39) | -0.21 (-0.38, -0.03) |
| TG | -0.18 (-0.29, -0.07) | 0.18 (0.02, 0.34) |
| LDL | -0.25 (-0.37, -0.14) | 0.67 (0.47, 0.87) |
| HDL | -0.17 (-0.26, -0.08) | 0.06 (0.07, 0.18) |
| SBP | 0.02 (0.05, 0.10) | 0.02 (-0.10, 0.13) |
| DBP | 0.14 (0.04, 0.24) | -0.23 (-0.37, -0.08) |

Association between SBP and HIV infection was robust to adjustment for potential confounders. Nevertheles, we cannot exclude residual or unknown confounding as a possible explanation. Equally, although the lack of association between ART and blood pressure seen in our analysis supports previously published results, only a small number of studies reported blood pressure measurements in both ART+ and ART- populations, suggesting these results require further evaluation.

We did not find an association between HIV infection, ART use and fasting blood glucose levels. Whereas this finding is consistent with findings from several large prospective and cross-sectional studies, it does not agree with findings from some large studies in populations of European descent that have reported associations between HIV infection, ART use and increased risk of T2D. Differences in cardiometabolic traits among ART users and non-users may have important implications for the management of people infected with HIV. Antiretroviral therapy has greatly improved the survival of HIV-infected patients living today; however, the mortality rates in HIV patients are still higher than in the general population and the proportion of deaths due to non-HIV-related causes including cardiometabolic diseases, is increasing. Dyslipidaemia is common among patients with HIV and has been shown to be associated with increased cardiovascular disease risk in this patient population. Furthermore, there is evidence to support an independent role of HIV infection on cardiometabolic disease risk, after accounting for traditional risk factors and exposure to ART.

In the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) cohort of 23,468 HIV-infected patients, higher total serum cholesterol and TGs and presence of diabetes were associated with an increased risk of myocardial infarction. Differences in average levels of cardiometabolic traits among subpopulations might also result in important differences in cardiovascular disease risk. For example, a 1-SD increase in LDL and HDL each were associated with a relative risk of 1.4 and 0.6, respectively, for coronary heart disease in the Atherosclerosis Risk in Communities Study (ARIC).
examining 12,336 individuals, indicating that a change of 0.6 SD in HDL and/or 0.4 SD in LDL observed in our meta-analysis may have important implications for modifying cardiovascular risk in these groups.\(^{105}\)

Findings from this meta-analysis should be interpreted within the context of its strengths and limitations. One of the strengths of the study is the large sample of individuals examined from different studies. We used a comprehensive and systematic search strategy examining two separate journal databases and contacted authors of studies for information on unpublished data and grey literature. Although the restriction of our search to only PubMed and EMBASE could be seen as a limitation, we feel that the combination of cited reference list searches and direct author contact helps ameliorate this concern. Furthermore, study eligibility was rigorously assessed by two independent reviewers, making assessment bias unlikely. However, we acknowledge that restricting this systematic review to English language articles may not be representative of the non-English literature. We were unable to correct for confounders at the individual level for all studies. Although none of the study-level characteristics and indices for study design substantially explained the heterogeneity among estimates from studies, we cannot rule out confounding at the individual level. Meta-regression approaches also have limited statistical power with sparse data. However, we were able to evaluate the potential effects of residual confounding with individual participant data analysis in a large cohort study, comprising nearly one-fifth of the overall data. Individual-level adjustment for confounders in a subset of data showed that SMDs are likely to be under-estimated (more conservative) in unadjusted analysis across most traits, suggesting that association estimates from summary data are unlikely to be overestimated. Unexplained heterogeneity could be attributed to one or more of several factors, including differences in study design and objective, differential confounding in each study due to age, sex, participant CD4 count or WHO stage, type and duration of ART treatment, co-infections or differences in data collection and laboratory assays. However, our findings are broadly consistent with published findings in populations of European descent,\(^{78,79,106}\) as well as studies using individual-level data to assess these associations.\(^{35,72,107}\)

An additional limitation of this study is the inability to delineate associations by ART drug class, due to insufficient data. Such analyses would be invaluable in understanding these associations, and their results would likely be of direct clinical relevance. Nevertheless, despite a lack of specific information on drug class, we identified associations between general ART use and differences in several cardiometabolic traits. It is likely that combining the impact of several different drugs in a single analysis would underestimate the individual effects of each drug.

Based on data presented here, the cardiometabolic consequences of HIV infection and ART exposure in SSA may be important. With a rapid increase in ART use over the past decade,\(^3\) an increasing number of SSA individuals are receiving treatment.\(^3\) As people live longer with HIV, it will become increasingly important to monitor their risk of other diseases. The HIV Medicine Association of the Infectious Disease Society of America, and the Adult AIDS Clinical Trials Group, published guidelines specifically for management of dyslipidaemia in HIV-infected individuals in 2003.\(^{15}\) Following this, the European AIDS Clinical Society (EACS) also published guidelines on the prevention and management of metabolic disease in HIV infection in 2008.\(^{108}\) Both these sets of guidelines have been based largely on evidence from studies in European populations and the impact of HIV infection and ART use on metabolic traits, and the utility of early screening and treatment in populations from SSA remains largely unknown. There is evidence to suggest that baseline metabolic profiles\(^20\) and associations between HIV and ART and metabolic risk factors may be different in different ethnic populations,\(^{109}\) with HIV-infected African-Americans being at higher risk of acute MI in comparison with individuals of European descent.\(^{18,19,169,110}\) This emphasises the need to examine these factors in SSA, where the burden of HIV infection is the greatest. Our results suggest that, with further evaluation, there may be a need to monitor cardiometabolic traits in HIV-infected individuals in SSA. One mechanism to achieve this, in the context of resource-poor settings, is to integrate care of chronic HIV with that of cardiometabolic diseases.\(^{111}\) Such routine monitoring has the potential to improve the management of cardiovascular disease among HIV-infected and ART-exposed individuals.\(^{111}\)

The results of this meta-analysis suggest that HIV infection and ART treatment are both associated with differences in cardiometabolic traits compared with HIV-uninfected or ART-naïve patients in SSA. Individual-level associations from a subset of 5,586 individuals, adjusted for several major cardiometabolic confounders, were generally consistent with study-level summary results, suggesting that the results from meta-analysis are likely to be robust to major confounding. To our knowledge, this is the first comprehensive study examining the association between HIV and cardiometabolic traits by a meta-analysis of published and unpublished data from SSA. These findings may have important implications for management of HIV in SSA, given the increasing use of ART and improved life expectancy among HIV-infected individuals in this region, and could provide a framework for further research aimed towards the development of specific guidelines for assessment and management of cardiometabolic risk in HIV-infected individuals in the region. More comprehensive analyses, including the collection of prospective
observational data, and a pooled analysis of individual-level cross-sectional data from the region are needed to clarify these findings and reliably assess the need for monitoring and managing cardiometabolic risk in populations in SSA.

**Supplementary Data**

Supplementary data are available at IJE online.

**Acknowledgements**

Clement Adebamowo, Adewbowale Adeyemo, Morris Agaba, Albert Amoah, Felix Assah, Naby Balde, Inês Barroso, Joram Buza, Bilkish Cassim, Tobias Chirwa, Francis Collins, Nigel J Crowther, Frank Dudbridge, Tonya Esterhuizen, Heiner Grosskurth, Andrew Haines, Sophie Hawkesworth, Branwen J Hennig, Robert Heyderman, Shabbar Jaffar, Pontiano Kaleebu, Anatoli Kamali, Saidi Kapiga, Elly Katabira, Kerstin Klipstein-Grobusch, Dominic Kwiatkowski, Naomi S Levitt, Edna Majaliwa, Patricia Marshall, Fredrick Mashili, Mary Mayige, Jean Claude Mbanya, Mark McCarthy, Sophie E Moore, Andrew Morris, Ayesha A Motala, Paula Munderi, Marina Njelekela, Shane Norris, Ousman Nyan, Moffat Nyirenda, John Oli, Michael Parker, Nasheeta Peer, Fraser Pirie, Andrew M Prentice, Kaushik Ramaiya, Raj Ramasar, Michele Ramsay, Charles Rotimi, Manjinder S Sandhu, Janet Seeley, Liam SMEETH, Eugene Sobngwi, Steve Tollman, Nicholas Wareham, Elizabeth H Young and Eleftheria Zeggini. Membership of the African Partnership for Chronic Disease Research.

**Funding**

This work was supported by the African Partnership for Chronic Disease Research strategic award from the UK Medical Research Council. The funders had no role in study design, data collection or analysis, decision to publish or preparation of the manuscript.

**Contributors**

M.S.S. had full access to all the data collected for the study, and had final responsibility for the decision to submit for publication. D.G.D. and M.S.S. conceived the study concept and design. D.G.D. and J.R. performed the literature review. D.G.D. collected summary data from the contributing centres and analysed the data. K.E. independently analysed the data and conducted checks for accuracy. All authors took part in the interpretation of the data. D.G.D., D.G. and M.S.S. drafted the article, and all authors provided critical revisions of the article for important intellectual content. All collaborators shared data and were given the opportunity to comment on the article.

Project steering committee: David G. Dillon, Naomi S. Levitt, Nigel Crowther, Moffat Nyirenda, Marina Njelekela, Kaushik Ramaiya, Ousman Nyan, Fredrick Mashili, Eugene Sobngwi, Clement Adebamowo, Janet Seeley, Elizabeth H. Young, Liam SMEETH, Ayesha A. Motala, Pontiano Kaleebu and Manjinder S. Sandhu.

Writing committee: Olanisun O. Adewole, Kathryn Anastos, Livio Azzoni, W. Henry Boom, Caterina Compostella, Joel A. Dave, Halima Dawood, Christian Erikstrup, Carla M. Fourie, Henrik Friis, Annamarie Kruger, John A. Idoko, Chris Longenecker, Suzanne Mbondi, Japheth E. Mukaya, Eugene Mutimura, Chiratidzo E. Ndlovu, George Praygod, Eric W. Pefura Yone, Mar Pujades-Rodriguez, Nyagosya Range, Mahmoud Sani, Aletta E. Schutte, Karen Sliwa, Phyllis Tien, Este H. Vorster, Corinna Walsh and Rutendo Zinyama.

**Conflict of interest:** None declared.

**KEY MESSAGES**

- Sub-Saharan Africa has the highest burden of HIV in the world and a rising prevalence of cardiometabolic disease.
- We assessed the associations among HIV, ART and cardiometabolic traits in 29,755 individuals from 49 published and 3 unpublished studies, including an individual-level analysis of 5,586 participants.
- Our results are broadly consistent with results from populations of European descent, and suggest differences in cardiometabolic traits between HIV-infected and uninfected individuals in sub-Saharan Africa, which might be modified by ART use.
- These findings provide a framework for further research aimed towards the development of specific guidelines for the assessment and management of cardiometabolic risk in HIV-infected individuals in the region.
References

1. WHO. Progress Report 2011: Global HIV/AIDS Response. Geneva: WHO, 2011.
2. WHO. More Developing Countries Show Universal Access to HIV/AIDS Services is Possible. Geneva: WHO, 2010.
3. UNAIDS. UNAIDS Report on the Global AIDS Epidemic 2010. 2010 www.unaids.org/documents/20101123_globalreport_em.pdf (12 June 2011, date last accessed).
4. Negin J, Barnighausen T, Lundgren JD, Mills EJ. Aging with HIV in Africa: the challenges of living longer. AIDS 2012;26(Suppl 1):S1–S5.
5. de-Graft A, Boynton P, Alanga LC. Developing effective chronic disease interventions in Africa: Insights from Ghana and Cameroon. Global Health 2010;6:6.
6. WHO. http://www.who.int/healthinfo/global_burden_disease/projections/en/index.html (3 May 2011, date last accessed).
7. Mbanya JC, Kengne AP, Assah F. Diabetes care in Africa. Diabet Med 2003;18:628–629.
8. Beaglehole R, Yach D. Globalisation and the prevention and control of noncommunicable disease: the neglected chronic diseases of adults. Lancet 2003;362:903–908.
9. Mahon D, Waswa L, Baisley K, Karabarinde A, Unwin N, Groskurth H. Distribution of hyperglycaemia and related cardiovascular disease risk factors in low-income countries: a cross-sectional population-based survey in rural Uganda. Int J Epidemiol 2011;40:60–71.
10. De Wit S, Sabin CA, Weber R et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008;31:1224–1229.
11. Brown TT, Cole SR, Li X et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005;165:1179–1184.
12. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycaemia, hyperlipidaemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000;160:2050–2056.
13. Klein D, Hurler LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002;30:471–477.
14. Fries-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993–2003.
15. Dube MP, Stein JH, Aberg JA et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003;3:613–627.
16. Omeh B, Sempa J, Castelnuovo B, Opio K et al. Prevalence of HIV-Associated Metabolic Abnormalities among Patients Taking First-Line Antiretroviral Therapy in Uganda. ISBN AIDS 2012:20126.
17. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007;92:2506–2512.
18. Schuster D, Gaillard T, Osei K. The cardiometabolic syndrome in persons of the African diaspora: challenges and opportunities. J Cardiometab Syndr 2007;2:260–266.
19. Goedcke J, Utzschneider K, Faulenbach M et al. Ethnic differences in serum lipoproteins and their determinants in South African women. Metabolism 2010;59:1341–1350.
20. Schutte AE, Huismann HW, van Rooyen JM et al. A significant decline in IGF-1 may predispose young Africans to subsequent cardiometabolic vulnerability. J Clin Endocrinol Metab 2010;95:2503–2507.
21. Peeters M. The genetic variability of HIV-1 and its implications. Transfus Clin Biol 2001;8:222–225.
22. Gaschen B, Taylor J, Yusim K et al. Diversity considerations in HIV-1 vaccine selection. Science 2002;296:2354–2360.
23. De Maria N, Colantoni A, Iddilman R, Friedlander L, Harig J, Van Thiel D. Impaired response to high-dose interferon treatment in African-Americans with chronic hepatitis C. Hepatogastroenterology 2002;49:788–792.
24. World Health Statistics. 2008 http://www.who.int/whosis/whostat/2008/en/index.html (7 May 2011, date last accessed).
25. Asiki G, Murphy G, Nakiyangi-Miuro J et al. Data Resource Profile: The General Population Cohort (GPC) in rural South-western Uganda; a platform for communicable and non communicable diseases studies. Int J Epidemiol 2013.
26. Kengeya-Kayondo JF, Kamali A, Nunn AJ, Ruberantwari A, Wagner HU, Mulder DW. Incidence of HIV-1 infection in adults and socio-demographic characteristics of seroconverters in a rural population in Uganda: 1990–1994. Int J Epidemiol 1996;25:1077–1082.
27. Cohen J. Statistical Analysis for the Behavioral Sciences. Hillsdale, NJ: Erlbaum, 1988.
28. Stat Med. 2002;21:1539–1558.
29. Addo A, Marquis G, Larkey A, Perez-Escamilla R, Mazur R, Harding K. Food insecurity and perceived stress but not HIV infection are independently associated with lower energy intake among lactating Ghanaian women. Matern Child Nutr 2011;7:80–91.
30. Adewole O, Eze S, Betiku Y et al. Lipid profile in HIV/AIDS patients in Nigeria. Afr J Health Sci 2010;18:144–150.
31. Agaba E, Agaba P, Sirisena N, Anteyi E, Idoko J. Renal disease in the acquired immunodeficiency syndrome in north central Nigeria. Nig J Med 2003;12:20–25.
32. Ahoua L, Umutoni C, Huerga H et al. Nutrition outcomes of HIV-infected malnourished adults treated with ready-to-use therapeutic food in sub-Saharan Africa: a longitudinal study. J Int AIDS Soc 2011;14:2.
33. Awotedu K, Ekpebegh C, Longo-Mbenza B, Iputo J. Prevalence of metabolic syndrome assessed by IDF and NCEP ATP 111 criteria and determinants of insulin resistance among HIV patients in the Eastern Cape Province of South Africa. Diabetes Metab Syndr 2010;4:210–214.
34. Becker A, Jacobson B, Singh S et al. The Thrombotic Profile of Treatment-Naive HIV-Positive Black South Africans With Acute Coronary Syndromes. Clin Appl Thromb Hemost 2011;17:264–272.
35. Buchacz K, Weidle P, Moore D et al. Changes in Lipid Profile Over 24 Months Among Adults on First-Line Highly Active Antiretroviral Therapy in the Home-Based AIDS Care Program in Rural Uganda. J Acquir Immune Defic Syndr 2008;47:304–311.
36. Ceffa S, Buonomo E, Altan A et al. Seroprevalence of HHV8 in a cohort of HIV-negative and HIV-positive patients in Mozambique. Ann Ig 2007;19:519–23.
**Cardiovascular Risk and Body-Fat**

Wallis R, Kyambadde P, Johnson J 2011; 

Vorster H, Kruger A, Margetts B 2011; 

Thompson V, Medard B, Taseera K 2011; 

Sliwa K, Forster O, Tibazarwa K 2011; 

Scarcella P, Buonomo E, Zimba I et al 2011; 

Fontas E, van Leth F, Sabin C et al 2011; 

AIDS Res Hum Retroviruses 2011; 

AIDS 2011; 

J Acquir Immune Defic Syndr 2011; 

AIDS 2011; 

AIDS Res Hum Retroviruses 2011; 

Internat J Cardiol 2011; 

Thompson V, Medard B, Taseera K et al. Regional anthropometry changes in antiretroviral-naive persons initiating a zidovudine-containing regimen in Mbarara, Uganda. AIDS Res Hum Retroviruses 2011; 27:785–91.

Vorster H, Kruger A, Margetts B et al. The nutritional status of asymptomatic HIV-infected African: direction for dietary intervention? Public Health Nutr 2004; 7: 1055–64.

Wallis R, Kyambadde P, Johnson J et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004; 18:257–64.

Yusuf S, Islam S, Chow C et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological study. Lancet 2011; 378:1231–43.

Riddler S, Smit E, Cole S et al. Impact of HIV Infection and HAART on Serum Lipids in Men. JAMA 2003; 289: 2978–82.

Grinspoon S, Carr A. Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults. N Engl J Med 2005; 353:48–62.

Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74:1045–52.

Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351:1881–83.

Hill A, Sawyer W, Gazzard B. Effects of First-Line Use of Nucleoside Analogues, Efavirenz, and Ritonav-Boosted Protease Inhibitors on Lipid Levels. HIV Clin Trials 2009; 10:1–12.

Riddler S, Li X, Chu H et al. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med 2007; 8:280–87.

Anastos L, Lu D, Shi Q et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr 2007; 45:34–42.

Barth R, van der Loeff M, Schuurman R, Hoepelman A, Wensing A. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010; 10: 155–66.

Fontas E, van Leth F, Sabin C et al. Lipid Profiles in HIV-Infected Patients Receiving Combination Antiretroviral Therapy: Are Different Antiretroviral Drugs Associated with Different Lipid Profiles? J Infect Dis 2004; 189: 1056–74.

Young J, Weber R, Rickenbach M et al. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther 2005; 10:585–91.

Grunfeld C, Rimland D, Gilbert C et al. Association of Upper Trunk and Visceral Adipose Tissue Volume With Insulin Resistance in Control and HIV-Infected Subjects in the FRAM Study. J Acquir Immune Defic Syndr 2007; 46: 283–90.

Maas J, Dukers N, Krol A et al. Body Mass Index Course in Asymptomatic HIV-Infected Homosexual Men and the Predictive Value of a Decrease of Body Mass Index for Progression to AIDS. J Acquir Immune Defic Syndr 1998; 19:254–59.

Grunfeld C, Saag M, Cofrancesco J Jr et al. Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy. AIDS 2010; 24:1717–26.

Gazzaruso C, Bruno R, Garzaniti A et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003; 21:1377–82.

Bergersen B, Sandvik L, Dunlop O, Birkeland K, Bruun J. Prevalence of Hypertension in HIV-Positive Patients on Highly Active Retroviral Therapy (HAART) Compared with HAART-Naive and HIV-Negative Controls: Results from a Norwegian Study of 721 Patients. Eur J Clin Microbiol Infect Dis 2003; 22:731–36.

Jerico C, Knobel H, Montero M et al. Hypertension in HIV-Infected Patients: Prevalence and Related Factors. Am J Hypertens 2005; 18:1396–401.

Schutte AE, Schutte R, Huisman HW et al. Are behavioural risk factors to be blamed for the conversion from optimal blood pressure to hypertensive status in Black South Africans? A 5-year prospective study. Int J Epidemiol 2012; 41:1114–23.

Bloomfield G, Hogan J, Keter A et al. Hypertension and Obesity as Cardiovascular Risk Factors among HIV Seropositive Patients in Western Kenya. PLoS One 2011; 6:67.

Tien P, Schneider M, Cole S et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women’s Intergery HIV Study. AIDS 2007; 21:1739–45.

Tien P, Schneider M, Cox C et al. Association of HIV Infection With Incident Diabetes Mellitus: Impact of Using Hemoglobin A1C as a Criterion for Diabetes. J Acquir Immune Defic Syndr 2012; 61:334–40.

Brar I, Shuter J, Thomas A, Daniels E, Absalon J. A comparison of factors associated with prevalent diabetes mellitus among HIV-infected antiretroviral-naive individuals versus individuals in the National Health and Nutritional Examination Survey cohort. J Acquir Immune Defic Syndr 2007; 45:66–71.

Butt A, Fultz S, Kwok C, Kelley D, Skanderson M, Justice A. Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection. Hepatology 2004; 40:15–19.

Tien PC, Schneider MF, Cox C et al. Association of HIV Infection With Incident Diabetes Mellitus: Impact of Using Hemoglobin A1C as a Criterion for Diabetes. J Acquir Immune Defic Syndr 2012; 61:334–40.

Kim PS, Woods C, Geogoff P et al. A1C underestimates glycemia in HIV infection. Diabetes Care 2009; 32:1591–93.
ASSOCIATION OF HIV AND ART WITH CARDIOMETABOLIC TRAITS IN SUB-SAHARAN AFRICA

102 Lohse N, Hansen AB, Pedersen G et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. *Ann Intern Med* 2007;146:87–95.

103 Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. *Ann Intern Med* 2006;145:397–406.

104 Hadigan C, Meigs JB, Corcoran C et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. *Clin Infect Dis* 2001;32:130–39.

105 Sharrett AR, Ballantyne CM, Coady SA et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. *Circulation* 2001;104:1108–13.

106 Islam F, Wu J, Jansson J, Wilson D. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. *Br HIV Assoc* 2012;13:453–68.

107 Fourie C, Rooyen J, Kruger A, Schutte A. Lipid Abnormalities in a Never-Treated HIV-1 Subtype C-Infected African Population. *Lipids* 2010;45:73–80.

108 Lundgren JD, Battegay M, Behrens G et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. *HIV Med* 2008;9:72–81.

109 Currier J, Scherzer R, Bacchetti P et al. Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women. *J Acquir Immune Defic Syndr* 2008;48:35–43.

110 Triant V, Lee H, Hadigan C, Grinspoon S. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. *J Clin Endocrinol Metab* 2007;92:2506–12.

111 Beaglehole R, Epping-Jordan J, Patel V et al. Improving the prevention and management of chronic disease in low-income and middle-income countries: a priority for primary health care. *Lancet* 2008;372:940–49.